{"id":71456,"date":"2026-05-20T12:05:00","date_gmt":"2026-05-20T12:05:00","guid":{"rendered":"https:\/\/medsbase.com\/adipotide-ftpp\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"adipotide-ftpp","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/adipotide-ftpp\/","title":{"rendered":"Adipotide (FTPP \u2014 Pept\u00eddeo Pr\u00f3-Apopt\u00f3tico Direcionado a Gordura)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 Adipotide (FTPP)?<\/h3>\n<p style=\"margin: 0;\"><strong>Adipotide<\/strong> (tamb\u00e9m chamado <strong>FTPP<\/strong> \u2014 &#8220;Fat-Targeted Pro-apoptotic Peptide&#8221;) is a synthetic 25-amino-acid chimeric peptide developed by <strong>Kolonin, Arap e Pasqualini<\/strong> no MD Anderson Cancer Center. Ele funde dois dom\u00ednios funcionalmente distintos: um pept\u00eddeo de homing c\u00edclico <strong>CKGGRAKDC<\/strong> que se liga \u00e0 prohibina-1 (e \u00e0 anexina A2) no endot\u00e9lio dos capilares do tecido adiposo branco, e um pept\u00eddeo pr\u00f3-apopt\u00f3tico \u03b1-helical em estereois\u00f4mero D <strong>D(KLAKLAK)<sub>2<\/sub><\/strong> que perturba as membranas mitocondriais. A quimera fundida tem como alvo seletivo a vasculatura que alimenta o tecido adiposo branco e desencadeia apoptose endotelial, privando os adip\u00f3citos de suprimento sangu\u00edneo e produzindo r\u00e1pida perda de massa de tecido adiposo. Publicado em macacos rhesus obesos (Barnhart et al. 2011, <em>Science Translational Medicine<\/em>) \u2014 ~11% de perda de peso corporal em 4 semanas. <strong>Advert\u00eancia:<\/strong> documented nephrotoxicity in primate studies is the major translational limitation, and a Phase I human cancer trial (2014\u20132016) had limited published outcomes. For clinical studies use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Peptidomim\u00e9tico quim\u00e9rico sint\u00e9tico de 25 amino\u00e1cidos; dom\u00ednio de homing + dom\u00ednio pr\u00f3-apopt\u00f3tico unidos por ligante GG; <em>pept\u00eddeo pr\u00f3-apopt\u00f3tico direcionado \u00e0 gordura<\/em><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Adipotide \/ FTPP (Pept\u00eddeo Pr\u00f3-Apopt\u00f3tico Direcionado \u00e0 Gordura); sin\u00f4nimos: Pept\u00eddeo-1 direcionado \u00e0 prohibina + D(KLAKLAK)<sub>2<\/sub> quimera; CKGGRAKDC-GG-D(KLAKLAK)<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pharmaceutical-grade chimeric peptide \u2014 no single canonical CAS. Some supplier listings cite 1422956-49-3; identification primarily by published sequence (CKGGRAKDC-GG-D(KLAKLAK)<sub>2<\/sub>) em vez do CAS. Consulte o COA para identifica\u00e7\u00e3o espec\u00edfica do lote.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys (dissulfeto Cys1\u2013Cys9 ciclizado, o motivo de homing de liga\u00e7\u00e3o \u00e0 prohibina \u201cCKGGRAKDC\u201d) \u2014 Ligante Gly-Gly \u2014 D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys (o pept\u00eddeo pr\u00f3-apopt\u00f3tico \u03b1-helical D(KLAKLAK)<sub>2<\/sub>). Comprimento total: 25 res\u00edduos de amino\u00e1cidos (9 + 2 + 14).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~2.611 Da (m\u00e9dia calculada; relatado como 2.500\u20132.611 Da em fontes publicadas)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pept\u00eddeo quim\u00e9rico \u2014 sequ\u00eancia CKGGRAKDC-GG-D(KLAKLAK)<sub>2<\/sub>; massa molecular aproximada derivada da sequ\u00eancia ~C<sub>114<\/sub>H<sub>196<\/sub>N<sub>40<\/sub>O<sub>26<\/sub>S<sub>2<\/sub>; massa molecular publicada ~2.611 Da (forma c\u00edclica de dissulfeto). Nenhum CAS can\u00f4nico Sigma; identifica\u00e7\u00e3o por sequ\u00eancia + COA.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Apoptose direcionada em duas etapas<\/strong>. (1) O dom\u00ednio de homing c\u00edclico CKGGRAKDC se liga \u00e0 prohibina-1 \u2014 uma prote\u00edna chaperona mitocondrial que \u00e9 expressa de forma incomum na <em>superf\u00edcie<\/em> das c\u00e9lulas endoteliais capilares que suprem o tecido adiposo branco (identificado por Kolonin et al. 2004 em triagem in-vivo por phage-display) \u2014 e tamb\u00e9m \u00e0 anexina A2 na mesma vasculatura. (2) Ligado \u00e0 superf\u00edcie celular, o quimera \u00e9 internalizado, e o dom\u00ednio pr\u00f3-apopt\u00f3tico \u03b1-helical D(KLAKLAK)<sub>2<\/sub> desestabiliza a membrana mitocondrial da c\u00e9lula endotelial por meio de intera\u00e7\u00e3o direta com a membrana. Colapso mitocondrial \u2192 apoptose mediada por caspases da vasculatura adiposa \u2192 priva\u00e7\u00e3o de suprimento sangu\u00edneo aos adip\u00f3citos \u2192 perda de massa do tecido adiposo ao longo de dias a semanas.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estereoqu\u00edmica de D-Amino\u00e1cidos<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">O dom\u00ednio pr\u00f3-apopt\u00f3tico KLAKLAKKLAKLAK \u00e9 sintetizado exclusivamente em <strong>Estereoqu\u00edmica de amino\u00e1cidos D<\/strong> (res\u00edduos em imagem espelhada). A estereoqu\u00edmica D confere resist\u00eancia a proteases \u2014 as proteases do hospedeiro reconhecem apenas amino\u00e1cidos L \u2014 prolongando a meia-vida in vivo do dom\u00ednio killer em rela\u00e7\u00e3o \u00e0 forma natural L. O dom\u00ednio de homing (CKGGRAKDC) est\u00e1 na estereoqu\u00edmica normal de amino\u00e1cidos L porque precisa se ligar a uma prote\u00edna do hospedeiro (proibitina-1) na geometria can\u00f4nica receptor-ligante.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Documented Toxicity (studies-relevant)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Nefrotoxicidade<\/strong> was documented in the obese-rhesus-monkey study (Barnhart et\u00a0al. 2011) and is the leading translational limitation. The kidney expresses prohibitin and is highly vascularised, so off-target homing of the chimera to renal vasculature produces dose-dependent renal injury. The MD Anderson group repositioned the compound for cancer rather than obesity precisely because the risk-benefit balance is more favourable in a cancer-treatment context than in an elective-fat-loss context. Users in any in-vivo protocol with Adipotide should include comprehensive renal-function monitoring (BUN, creatinine, urinalysis).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials. Synthesis is technically demanding (D-amino-acid Fmoc-SPPS + cyclic disulfide closure of the homing domain) \u2014 purity grade matters more for this compound than for most.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC); espectrometria de massa MALDI-TOF confirma ~2.611 Da. A forma\u00e7\u00e3o da ponte dissulfeto do dom\u00ednio de homing c\u00edclico foi confirmada por compara\u00e7\u00e3o de massa reduzida vs n\u00e3o reduzida. COA dispon\u00edvel mediante solicita\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sol\u00favel em \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril e PBS a \u22652 mg\/mL; sol\u00favel em DMSO a \u226510 mg\/mL para prepara\u00e7\u00e3o de estoque in vitro. O anfip\u00e1tico D(KLAKLAK)<sub>2<\/sub> dom\u00ednio tem propriedades semelhantes a surfactantes \u2014 solu\u00e7\u00f5es podem apresentar espuma transit\u00f3ria na reconstitui\u00e7\u00e3o inicial; deixe assentar antes da retirada.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C fechado para estoque de trabalho de curto prazo; \u221220 \u00b0C para armazenamento de longo prazo (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). Aquoso reconstitu\u00eddo: 2\u20138 \u00b0C, use dentro de ~30 dias. Proteger da luz. Evite ciclos repetidos de congelamento-descongelamento \u2014 ciclos cumulativos podem causar desarranjo da ponte dissulfeto Cys1\u2013Cys9.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 Adipotide \/ FTPP?<\/h2>\n<p><strong>Adipotide<\/strong> (tamb\u00e9m chamado <strong>FTPP<\/strong> \u2014 \u201cPept\u00eddeo Pr\u00f3-apopt\u00f3tico Direcionado a Gordura\u201d) \u00e9 um peptidomim\u00e9tico quim\u00e9rico sint\u00e9tico de 25 amino\u00e1cidos desenvolvido no <strong>MD Anderson Cancer Center<\/strong> por Mikhail Kolonin, Wadih Arap e Renata Pasqualini. O composto representa um dos exemplos mais claros de <strong>design racional de pept\u00eddeo quim\u00e9rico para drogas<\/strong> in modern peptide pharmacology: a tissue-specific homing domain (identified by in-vivo phage display) is covalently fused to a generic killer domain (a pro-apoptotic mitochondrion-disrupting \u03b1-helical peptide), producing a chimera that delivers the killer activity selectively to the target tissue. The two functional domains and the design logic:<\/p>\n<p><strong>1. CKGGRAKDC \u2014 o pept\u00eddeo de homing que se liga \u00e0 prohibina.<\/strong> Kolonin et al. (2004) utilizaram triagem por exibi\u00e7\u00e3o de fagos in vivo em camundongos obesos para identificar um pept\u00eddeo c\u00edclico de 9 res\u00edduos (sequ\u00eancia Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys, com uma ponte dissulfeto Cys1-Cys9 que restringe a geometria) que se liga seletivamente \u00e0 vasculatura do tecido adiposo branco. O alvo de liga\u00e7\u00e3o foi posteriormente identificado como <strong>prohibitin-1<\/strong> (PHB1) \u2014 uma prote\u00edna semelhante a chaperona normalmente residente na membrana mitocondrial que, no endot\u00e9lio do tecido adiposo branco, tamb\u00e9m \u00e9 expressa na superf\u00edcie celular e acess\u00edvel a ligantes circulantes. A anexina A2 foi identificada como um parceiro de liga\u00e7\u00e3o secund\u00e1rio na mesma vasculatura. O dom\u00ednio de homing CKGGRAKDC \u00e9 o c\u00f3digo postal molecular que direciona a quimera especificamente para os capilares do tecido adiposo, em vez do endot\u00e9lio sist\u00eamico geral. <strong>2. D(KLAKLAK)<sub>2<\/sub> \u2014 o pept\u00eddeo \u03b1-helicoidal pr\u00f3-apopt\u00f3tico.<\/strong> The 14-residue D-amino-acid \u03b1-helical peptide D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys-D-Lys-D-Leu-D-Ala-D-Lys-D-Leu-D-Ala-D-Lys is a synthetic membrane-disrupting peptide (originally developed in cancer-targeting studies by Ellerby et\u00a0al. 1999). The amphipathic \u03b1-helical geometry causes the peptide to insert into membranes; the D-amino-acid stereochemistry confers protease-resistance in vivo. Crucially, the killer activity is <em>n\u00e3o<\/em> seletiva para qualquer tipo celular espec\u00edfico \u2014 o pept\u00eddeo ir\u00e1 perturbar membranas mitocondriais em praticamente qualquer c\u00e9lula que penetre \u2014 raz\u00e3o pela qual o pareamento com um dom\u00ednio de homing \u00e9 necess\u00e1rio para utilidade terap\u00eautica. <strong>3. Linker GG.<\/strong> The two functional domains are joined by a simple di-glycine linker that provides flexible spacing and avoids steric interference between the homing and killer functions. The combined chimera (CKGGRAKDC-GG-D(KLAKLAK)<sub>2<\/sub>, ~2.611 Da) foi caracterizada em macacos rhesus obesos no artigo seminal de Barnhart et al. (2011) em <em>Science Translational Medicine<\/em> \u2014 os animais perderam aproximadamente 11% do peso corporal ao longo de 4 semanas de dosagem di\u00e1ria por via SC, com melhorias concomitantes na sensibilidade \u00e0 insulina. No entanto, o mesmo estudo e trabalhos subsequentes documentaram <strong>nefrotoxicidade dose-dependente<\/strong>: the kidney has high prohibitin expression and is densely vascularised, so off-target homing of the chimera to renal vasculature produces renal-cortex tubular damage. The MD Anderson group repositioned Adipotide for human oncology rather than obesity, and a Phase I clinical trial in patients with metastatic prostate cancer was conducted 2014\u20132016 with limited published outcomes. The compound remains a tool today \u2014 extensively cited as a reference example of chimeric peptide drug design and the canonical pharmacological tool for studying targeted adipose-vascular apoptosis. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Apoptose Direcionada ao Tecido da Vasculatura Adiposa<\/h2>\n<p>O mecanismo do Adipotide \u00e9 um dos mais caracterizados na farmacologia de pept\u00eddeos quim\u00e9ricos:<\/p>\n<ul>\n<li><strong>Direcionamento vascular via liga\u00e7\u00e3o \u00e0 prohibitin-1<\/strong> \u2014 O dom\u00ednio de homing CKGGRAKDC se liga \u00e0 prohibitin-1 expressa na superf\u00edcie das c\u00e9lulas endoteliais capilares que suprem o tecido adiposo branco. A prohibitin-1 \u00e9 normalmente uma chaperona da membrana interna mitocondrial, mas no endot\u00e9lio do TAT ela \u00e9 expressa de forma an\u00f4mala na folha externa da membrana plasm\u00e1tica, tornando-a acess\u00edvel a ligantes circulantes. O motivo CKGGRAKDC \u00e9 altamente seletivo para o pool de prohibitin do endot\u00e9lio do TAT em rela\u00e7\u00e3o a outros contextos de express\u00e3o de prohibitin \u2014 estudos de liga\u00e7\u00e3o publicados mostram um enriquecimento de ~10\u2013100 vezes do Adipotide na vasculatura do TAT em rela\u00e7\u00e3o \u00e0 vasculatura sist\u00eamica gen\u00e9rica.<\/li>\n<li><strong>Annexina A2 como parceiro de liga\u00e7\u00e3o secund\u00e1rio<\/strong> \u2014 Trabalhos publicados subsequentes identificaram a annexina A2 como um parceiro de liga\u00e7\u00e3o adicional do dom\u00ednio de homing CKGGRAKDC no mesmo endot\u00e9lio do TAT. O padr\u00e3o de reconhecimento duplo de prohibitin \/ annexina A2 pode contribuir para o perfil de seletividade do Adipotide.<\/li>\n<li><strong>Internaliza\u00e7\u00e3o e entrega citos\u00f3lica do dom\u00ednio killer<\/strong> \u2014 Ap\u00f3s a liga\u00e7\u00e3o do CKGGRAKDC aos receptores da superf\u00edcie celular endotelial, o quimera \u00e9 internalizado por endocitose. O D(KLAKLAK) anfip\u00e1tico<sub>2<\/sub> o dom\u00ednio \u00e9 liberado no citosol via escape endossomal e, a partir da\u00ed, acessa a membrana externa mitocondrial.<\/li>\n<li><strong>Disrup\u00e7\u00e3o da membrana mitocondrial e apoptose<\/strong> \u2014 A geometria anfip\u00e1tica \u03b1-helical de D(KLAKLAK)<sub>2<\/sub> promove a inser\u00e7\u00e3o na membrana externa mitocondrial, com subsequente despolariza\u00e7\u00e3o, libera\u00e7\u00e3o de citocromo c e ativa\u00e7\u00e3o da cascata intr\u00ednseca de apoptose por caspases. A estereoqu\u00edmica de amino\u00e1cidos D evita a degrada\u00e7\u00e3o proteol\u00edtica do pept\u00eddeo killer antes que ele atinja seu alvo.<\/li>\n<li><strong>Abla\u00e7\u00e3o vascular \u2192 inani\u00e7\u00e3o de adip\u00f3citos \u2192 perda de massa do tecido adiposo<\/strong> \u2014 A apoptose das c\u00e9lulas endoteliais que nutrem o tecido adiposo branco (WAT) priva os adip\u00f3citos de suprimento sangu\u00edneo. Ao longo de dias a semanas, os adip\u00f3citos sofrem morte celular secund\u00e1ria por priva\u00e7\u00e3o metab\u00f3lica, e o tecido adiposo diminui. O fen\u00f3tipo macrosc\u00f3pico \u00e9 a redu\u00e7\u00e3o de peso corporal dose-dependente, sem a mobiliza\u00e7\u00e3o lip\u00eddica aguda observada com agentes lipol\u00edticos cl\u00e1ssicos como AOD-9604 ou agonistas \u03b23-adren\u00e9rgicos.<\/li>\n<li><strong>O problema da nefrotoxicidade<\/strong> \u2014 O rim possui densidade vascular muito alta e alta express\u00e3o de prohibitina. A homing off-target do Adipotide para capilares renais produz danos tubulares no c\u00f3rtex renal dose-dependentes em estudos com primatas (Barnhart et al. 2011). Esta \u00e9 a principal limita\u00e7\u00e3o translacional do composto e o motivo pelo qual o programa de farmacologia da obesidade foi descontinuado em favor de aplica\u00e7\u00f5es em c\u00e2ncer, onde um equil\u00edbrio risco-benef\u00edcio mais agressivo \u00e9 aceit\u00e1vel.<\/li>\n<\/ul>\n<p>The combined mechanistic profile makes Adipotide uniquely useful for studies on the <em>contribui\u00e7\u00e3o vascular<\/em> contribution to adipose-tissue biology \u2014 distinct from studies on adipocyte-intrinsic lipolysis (the <a href=\"https:\/\/medsbase.com\/pt-br\/aod-9604\/\">AOD-9604<\/a> \/ \u03b23-AR) ou supress\u00e3o central do apetite mediada por GLP-1 (o eixo da fam\u00edlia <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a> \/ GLP-1 family axis). Users studying angiogenesis-vs-anti-angiogenesis approaches to obesity, or testing other targeted-apoptosis peptide constructs, use Adipotide as the canonical positive-control compound. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Adipotide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Design de f\u00e1rmacos pept\u00eddicos quim\u00e9ricos \u2014 o composto de refer\u00eancia can\u00f4nico<\/strong> \u2014 de longe o exemplo mais citado de uma quimera apopt\u00f3tica direcionada a tecidos na literatura publicada; composto de refer\u00eancia padr\u00e3o para o paradigma mais amplo de design de pept\u00eddeos terap\u00eauticos \u201choming-peptide + killer-peptide\u201d<\/li>\n<li><strong>White adipose tissue vasculature studies<\/strong> \u2014 Adipotide&#8217;s WAT-vasculature selectivity makes it the canonical tool for studying the role of vascular biology in adipose tissue mass regulation; used in studies that explores whether obesity could be approached through anti-angiogenic \/ vascular-targeted strategies rather than appetite-suppressive or lipolytic strategies<\/li>\n<li><strong>Biologia da prohibina e da anexina A2<\/strong> \u2014 o trabalho de identifica\u00e7\u00e3o do receptor homing (Kolonin 2004 em diante) estabeleceu a prohibina de superf\u00edcie como um marcador vascular; o Adipotide \u00e9 a ferramenta farmacol\u00f3gica padr\u00e3o para investigar abordagens direcionadas \u00e0 prohibina em cultura prim\u00e1ria de c\u00e9lulas endoteliais e em trabalhos in vivo<\/li>\n<li><strong>Farmacologia de pept\u00eddeos pr\u00f3-apopt\u00f3ticos de D-amino\u00e1cidos<\/strong> \u2014 D(KLAKLAK)<sub>2<\/sub> is the most-cited pro-apoptotic D-peptide in the literature; Adipotide is the most-cited chimera incorporating it; widely used in studies on protease-resistant peptide design<\/li>\n<li><strong>Obesity-pharmacology comparative studies<\/strong> \u2014 compara\u00e7\u00f5es publicadas de frente a frente entre o Adipotide e pept\u00eddeos lipol\u00edticos (AOD-9604), agonistas de GLP-1 (semaglutida, tirzepatida) e agonistas diretos de \u03b23-AR (mirabegrona) caracterizam os diferentes perfis de mecanismo para redu\u00e7\u00e3o da massa adiposa<\/li>\n<li><strong>Cancer \/ tumour-vasculature studies<\/strong> \u2014 after the obesity programme was discontinued, Adipotide and related chimeras were repositioned for prostate-cancer studies (Phase I trial 2014\u20132016); published studies has explored the same homing-killer paradigm targeting tumour-specific endothelial markers (RGD-containing homing peptides + D(KLAKLAK)<sub>2<\/sub> para abla\u00e7\u00e3o da vasculatura tumoral)<\/li>\n<li><strong>Targeted apoptosis pharmacology and drug-delivery studies<\/strong> \u2014 Adipotide \u00e9 o composto can\u00f4nico de controle positivo para novos constructos de pept\u00eddeos de apoptose direcionados a tecidos (quimeras CPP-toxina, conjugados anticorpo-toxina com cabe\u00e7as de guerra pept\u00eddicas, etc.)<\/li>\n<li><strong>Nephrotoxicity \/ vascular off-target studies<\/strong> \u2014 the documented kidney toxicity is itself a studies subject; published work has explored the basis of the renal off-target homing and tested second-generation Adipotide analogues with modified homing domains to reduce renal accumulation<\/li>\n<\/ul>\n<p>For broader context on fat-loss and adipose-biology peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-br\/aod-9604\/\">AOD-9604<\/a> (fragmento lipol\u00edtico exclusivo de hGH \u2014 compara\u00e7\u00e3o direta de mecanismo; direcionamento intr\u00ednseco ao adip\u00f3cito vs vascular), <a href=\"https:\/\/medsbase.com\/pt-br\/hgh-fragment-176-191\/\">Fragmento de HGH 176-191<\/a> (o fragmento lipol\u00edtico original n\u00e3o estabilizado), <a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">Semaglutide<\/a> (agonista do receptor GLP-1 \u2014 mecanismo de supress\u00e3o central do apetite), <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">Tirzepatide<\/a> (duplo GLP-1\/GIP \u2014 efeitos metab\u00f3licos mais amplos), e <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo metab\u00f3lico derivado mitocondrial). Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">peptides &amp; compounds catalog<\/a>, ou consulte o <a href=\"https:\/\/medsbase.com\/pt-br\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> A MedsBase oferece Adipotide\/FTPP em tr\u00eas tamanhos de frascos liofilizados calibrados para protocolos t\u00edpicos de pesquisa in vitro e in vivo. Cada concentra\u00e7\u00e3o est\u00e1 dispon\u00edvel em formatos de embalagem com 10 ou 20 frascos:. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Adipotide \/ FTPP in three lyophilized vial sizes calibrated to typical in-vitro and in-vivo protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Concentra\u00e7\u00e3o m\u00e9dia padr\u00e3o \u2014 protocolos in vivo em roedores com obesidade induzida por dieta (doses t\u00edpicas publicadas de 0,43 mg\/kg\/dia por via subcut\u00e2nea em ciclos de 4 semanas conforme Kolonin 2004), tamanhos de amostra de m\u00faltiplas coortes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Frasco de pesquisa de alta concentra\u00e7\u00e3o \u2014 protocolos de ciclo estendido\/m\u00faltiplas coortes, dosagem em escala de primatas (doses publicadas em macacos rhesus de 0,43 mg\/kg\/dia), pesquisa de mecanismo de a\u00e7\u00e3o em grandes coortes; menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-cycle \/ multi-cohort protocols, primate-scale dosing (rhesus published doses 0.43 mg\/kg\/d), large-cohort mechanism-of-action studies; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Todas as tr\u00eas concentra\u00e7\u00f5es s\u00e3o a mesma entidade qu\u00edmica (Adipotida liofilizada \/ FTPP, pureza \u226599% por HPLC, massa confirmada por MALDI-TOF em ~2.611 Da, dom\u00ednio de homing confirmado por dissulfeto c\u00edclico). O frasco de 10 mg oferece o menor custo por mg para protocolos in vivo em grande escala. <strong>Users conducting any in-vivo work with Adipotide should plan comprehensive renal-function monitoring (BUN, creatinine, urinalysis, histology where appropriate) from the outset, given the well-documented nephrotoxicity profile in primate studies.<\/strong> Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Como Comparar \u2014 Adipotide vs AOD-9604<\/h2>\n<p>s\u00e3o os dois pept\u00eddeos para pesquisa em perda de gordura mais bem caracterizados neste cat\u00e1logo, e eles atuam na biologia do tecido adiposo por mecanismos completamente diferentes. O Adipotide age na <a href=\"https:\/\/medsbase.com\/pt-br\/aod-9604\/\">AOD-9604<\/a> are the two best-characterised fat-loss peptides in this catalogue, and they target adipose-tissue biology through completely different mechanisms. Adipotide acts on the <em>que nutre o tecido adiposo \u2014 ablacionando seletivamente o endot\u00e9lio do tecido adiposo branco (WAT) via apoptose direcionada, privando os adip\u00f3citos de suprimento sangu\u00edneo. O AOD-9604 age no<\/em> tecido adiposo alimentador \u2014 abla\u00e7\u00e3o seletiva do endot\u00e9lio do tecido adiposo branco (TAB) via apoptose direcionada, privando os adip\u00f3citos de suprimento sangu\u00edneo. O AOD-9604 atua sobre <em>os pr\u00f3prios adip\u00f3citos<\/em> \u2014 driving lipolysis and suppressing lipogenesis via a \u03b23-AR-dependent mechanism (GHR-decoupled). The two compounds therefore probe completely different layers of adipose biology and are commonly used as positive controls in mechanism-of-action studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Adipotide\/FTPP<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AOD-9604<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe qu\u00edmica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">pept\u00eddeo quim\u00e9rico de 25 aa (dom\u00ednio de homing + GG + pept\u00eddeo D pr\u00f3-apopt\u00f3tico); dissulfeto c\u00edclico no dom\u00ednio de homing<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">pept\u00eddeo linear de 16 aa (fragmento C-terminal do hGH + Tyr N-terminal); dissulfeto interno \u00fanico<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2.611 Da<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1.815,1 Da<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Alvo celular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">endot\u00e9lio capilar do TAV (receptores de prohibina-1 + anexina A2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Adip\u00f3cito (receptor \u03b23-adren\u00e9rgico, hipotetizado)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Consequ\u00eancia celular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Apoptose do endot\u00e9lio vascular \u2192 fome do adip\u00f3cito \u2192 perda de massa tecidual<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ativa\u00e7\u00e3o da lip\u00f3lise (fosforila\u00e7\u00e3o da HSL) + supress\u00e3o da lipog\u00eanese em adip\u00f3citos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>In\u00edcio\/curso temporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lento \u2014 dias a semanas (apoptose \u2192 cascata de fome)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">R\u00e1pido \u2014 minutos a horas (ativa\u00e7\u00e3o da lip\u00f3lise)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efic\u00e1cia documentada in vivo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~11% de perda de peso corporal em 4 semanas em macacos rhesus obesos (Barnhart 2011)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estudo de fase IIb para obesidade n\u00e3o atingiu o endpoint de perda de peso (2007)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Toxicidade documentada<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Nefrotoxicidade<\/strong> \u2014 dano tubular dependente da dose no c\u00f3rtex renal em estudos com primatas; principal limita\u00e7\u00e3o translacional<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Geralmente bem tolerado em ensaios cl\u00ednicos; nenhuma toxicidade org\u00e2nica espec\u00edfica documentada na Fase II<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Vascular-targeted apoptosis studies, chimeric peptide drug design, anti-angiogenic obesity studies, oncology vascular ablation<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GHR-decoupled lipolysis pharmacology, structure-function HGH studies, \u03b23-AR-linked adipocyte signalling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on vascular contribution to adipose biology, chimeric peptide drug design, or targeted-apoptosis pharmacology, Adipotide is the canonical reference compound. For studies focused on direct adipocyte lipolysis isolated from GH-axis signalling, <a href=\"https:\/\/medsbase.com\/pt-br\/aod-9604\/\">AOD-9604<\/a> is the more targeted tool. The two compounds are mechanistically complementary and are commonly used as parallel positive controls in obesity-pharmacology mechanism studies. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene os frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo, congele frascos n\u00e3o abertos a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226518 meses a 2\u20138 \u00b0C). A dissulfura c\u00edclica do dom\u00ednio de homing \u00e9 est\u00e1vel no estado liofilizado. Proteger da luz. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injete \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado). Para um frasco de 2 mg, 1,0 mL de diluente produz uma solu\u00e7\u00e3o estoque de trabalho de 2 mg\/mL. Para um frasco de 5 mg, 1,0 mL produz 5 mg\/mL; 2,5 mL produz 2 mg\/mL. Para um frasco de 10 mg, 1,0 mL produz 10 mg\/mL (o limite pr\u00e1tico de solubilidade em tamp\u00e3o aquoso); 5,0 mL produz 2 mg\/mL. O Adipotide dissolve-se com agita\u00e7\u00e3o suave \u00e0 temperatura ambiente em 30\u201360 segundos; o anfip\u00e1tico D(KLAKLAK)<sub>2<\/sub> pode produzir espuma transit\u00f3ria na reconstitui\u00e7\u00e3o inicial \u2014 deixe assentar antes da retirada. <strong>N\u00e3o vortexar<\/strong> \u2014 high-shear mixing risks Cys1\u2013Cys9 disulfide-bond disruption of the homing domain. Once reconstituted, store the vial at 2\u20138 \u00b0C and use within 30 days. Protect from light. Avoid repeated freeze-thaw cycles of reconstituted material \u2014 cumulative cycles risk disulfide scrambling and loss of homing-domain target selectivity. Discard if cloudiness, particulates, or marked colour change appears. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>O que \u00e9 Adipotide e como ele difere de outros \u201cpept\u00eddeos para perda de gordura\u201d?<\/h3>\n<p>Adipotide (FTPP) \u00e9 o exemplo can\u00f4nico de uma <strong>abordagem de apoptose direcionada a vasos<\/strong> para redu\u00e7\u00e3o de tecido adiposo \u2014 completamente distinta mecanicamente dos pept\u00eddeos lipol\u00edticos (<a href=\"https:\/\/medsbase.com\/pt-br\/aod-9604\/\">AOD-9604<\/a>, agonistas \u03b23-AR), os pept\u00eddeos supressores centrais do apetite (<a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a>, <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">tirzepatide<\/a>, a fam\u00edlia GLP-1), e os pept\u00eddeos de balan\u00e7o energ\u00e9tico (<a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a>). Enquanto os pept\u00eddeos lipol\u00edticos ativam a mobiliza\u00e7\u00e3o lip\u00eddica intr\u00ednseca dos adip\u00f3citos, o Adipotide elimina o suprimento sangu\u00edneo <em>para<\/em> the adipocytes \u2014 a fundamentally different point of mechanistic intervention. It is the canonical tool for studying the vascular contribution to adipose-tissue biology. <\/p>\n<h3>What is the documented nephrotoxicity, and what does it mean for protocols?<\/h3>\n<p>Barnhart et al. (2011) e estudos subsequentes em primatas documentaram <strong>danos tubulares no c\u00f3rtex renal<\/strong> in Adipotide-treated rhesus monkeys. The mechanistic basis is straightforward: the kidney has very high vascular density and high prohibitin expression, so off-target homing of the chimera to renal capillaries produces the same vascular-apoptosis-then-starvation cascade as it produces in adipose tissue, but in a tissue where this is highly undesirable. This is the major translational limitation of the compound and is the reason the obesity-pharmacology programme was discontinued in favour of oncology repositioning (where a more aggressive risk-benefit balance is acceptable). Study protocols using Adipotide in vivo must include comprehensive renal-function monitoring \u2014 BUN, serum creatinine, urinalysis, and renal histology where appropriate. <\/p>\n<h3>What published dose ranges have been used in studies?<\/h3>\n<p>The Kolonin et\u00a0al. (2004) mouse work used 0.43 mg\/kg\/d SC for 4-week cycles. The Barnhart et\u00a0al. (2011) rhesus-monkey work used the same 0.43 mg\/kg\/d SC for 4 weeks, with concurrent renal-function monitoring. The Phase I human prostate-cancer trial (2014\u20132016) used escalating SC doses on a weekly or twice-weekly schedule. In-vitro endothelial-cell apoptosis assays typically use micromolar concentrations. Users should consult primary literature (Kolonin et\u00a0al. 2004, <em>Nature Medicine<\/em>; Barnhart et al. 2011, <em>Science Translational Medicine<\/em>) para orienta\u00e7\u00e3o de dosagem espec\u00edfica por esp\u00e9cie, modelo e endpoint. <\/p>\n<h3>Qual \u00e9 a estereoqu\u00edmica de amino\u00e1cidos D de D(KLAKLAK)?<sub>2<\/sub>, e por que isso importa?<\/h3>\n<p>O dom\u00ednio pr\u00f3-apopt\u00f3tico killer do Adipotide \u00e9 sintetizado exclusivamente em <strong>estereoqu\u00edmica de D-amino\u00e1cidos<\/strong> \u2014 vers\u00f5es em imagem espelhada dos L-amino\u00e1cidos naturais. O motivo \u00e9 a resist\u00eancia a proteases: as proteases celulares e circulantes reconhecem e degradam pept\u00eddeos baseados na estereoqu\u00edmica natural de L-amino\u00e1cidos, ent\u00e3o um pept\u00eddeo de D-amino\u00e1cidos \u00e9 essencialmente invis\u00edvel \u00e0 prote\u00f3lise do hospedeiro. Isso protege o dom\u00ednio killer da degrada\u00e7\u00e3o prematura antes de atingir seu alvo mitocondrial. O dom\u00ednio de homing (CKGGRAKDC) est\u00e1 na estereoqu\u00edmica normal de L-amino\u00e1cidos porque deve se ligar a uma prote\u00edna do hospedeiro (proibitina-1) na geometria can\u00f4nica receptor-ligante \u2014 a estereoqu\u00edmica D impediria completamente a liga\u00e7\u00e3o. Esse design de estereoqu\u00edmica dividida (dom\u00ednio L para liga\u00e7\u00e3o + dom\u00ednio D para resist\u00eancia a proteases) \u00e9 um motivo recorrente no design de pept\u00eddeos quim\u00e9ricos e \u00e9 uma das caracter\u00edsticas mais citadas do Adipotide. <\/p>\n<h3>Por que o Adipotide n\u00e3o \u00e9 aprovado pela FDA?<\/h3>\n<p>Adipotide is a compound that completed Phase I trials in human cancer patients (prostate cancer, 2014\u20132016) but has not progressed to large-scale Phase II\/III trials. The reasons are a combination of the documented nephrotoxicity (which limits the dose window in any human-subject context), the modest published efficacy data in the limited clinical work to date, and the relatively narrow indication (vascular-targeted apoptosis is mechanism-appropriate for certain cancer settings but the broader development pathway is unclear). The compound remains a tool today, widely used as the canonical chimeric peptide drug-design reference compound. <\/p>\n<h3>Como o Adipotide \u00e9 diferente do AOD-9604?<\/h3>\n<p>Completely different mechanisms despite both being &#8220;fat-loss peptides.&#8221; <a href=\"https:\/\/medsbase.com\/pt-br\/aod-9604\/\">AOD-9604<\/a> \u00e9 um fragmento C-terminal de 16 amino\u00e1cidos do hGH que ativa a lip\u00f3lise diretamente nos adip\u00f3citos via receptor \u03b23-adren\u00e9rgico (desacoplado do GHR). O Adipotide \u00e9 um pept\u00eddeo quim\u00e9rico de 25 amino\u00e1cidos que abla o suprimento sangu\u00edneo vascular <em>para<\/em> adipocytes via targeted endothelial apoptosis. AOD-9604 produces rapid acute lipolytic effects within hours; Adipotide produces slow tissue-mass reduction over days to weeks. AOD-9604 is generally well-tolerated; Adipotide has documented nephrotoxicity. Users studying obesity mechanisms often use both as parallel positive controls representing the two ends of the &#8220;adipocyte-intrinsic vs adipose-vascular&#8221; mechanistic spectrum. <\/p>\n<h3>Can Adipotide be combined with other fat-loss peptides in protocols?<\/h3>\n<p>Sim \u2014 o Adipotide \u00e9 mecanicamente ortogonal a pept\u00eddeos lipol\u00edticos (<a href=\"https:\/\/medsbase.com\/pt-br\/aod-9604\/\">AOD-9604<\/a>), pept\u00eddeos do eixo GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-br\/semaglutide\/\">semaglutida<\/a>, <a href=\"https:\/\/medsbase.com\/pt-br\/tirzepatide\/\">tirzepatide<\/a>) e pept\u00eddeos metab\u00f3licos (<a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a>), so combinations are mechanistically rational for protocols that aim to dissect different layers of adipose biology. The most-published combinations in the limited literature are Adipotide + GLP-1 agonist (testing whether vascular ablation adds to appetite-suppression-driven weight loss). Reconstitute each separately and follow each compound&#8217;s specific storage rules. As always with Adipotide in vivo, comprehensive renal-function monitoring is required regardless of the co-administered compound. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre Adipotide\/FTPP e o \u201cpept\u00eddeo direcionado \u00e0 prohibina-1\u201d (PTP1)?<\/h3>\n<p>O PTP1 \u00e9 apenas o pept\u00eddeo de direcionamento \u2014 apenas a sequ\u00eancia c\u00edclica CKGGRAKDC, sem o dom\u00ednio pr\u00f3-apopt\u00f3tico D(KLAKLAK)<sub>2<\/sub> anexado. O PTP1 sozinho se liga \u00e0 prohibina-1 da vasculatura do tecido adiposo branco (WAT), mas n\u00e3o desencadeia qualquer atividade apopt\u00f3tica \u2014 \u00e9 apenas o c\u00f3digo postal molecular sem a ogiva. O Adipotide\/FTPP \u00e9 a quimera completa (CKGGRAKDC + ligador GG + D(KLAKLAK)<sub>2<\/sub>) that combines the homing function with the killer function. Users studying the homing-domain biology in isolation use PTP1; users studying the integrated targeted-apoptosis effect use the full Adipotide chimera. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Adipose Biology and Fat-Loss Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/aod-9604\/\"><strong>AOD-9604<\/strong><\/a> \u2014 Fragmento C-terminal lipol\u00edtico do hGH \u2014 compara\u00e7\u00e3o direta de mecanismo; direcionamento intr\u00ednseco ao adip\u00f3cito vs direcionamento vascular<\/li>\n<li><a href=\"\/pt-br\/hgh-fragment-176-191\/\"><strong>Fragmento de HGH 176-191<\/strong><\/a> \u2014 Fragmento lipol\u00edtico n\u00e3o estabilizado \u2014 ferramenta alternativa de lip\u00f3lise direta ao adip\u00f3cito<\/li>\n<li><a href=\"\/pt-br\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Agonista do receptor GLP-1 \u2014 mecanismo central de supress\u00e3o do apetite<\/li>\n<li><a href=\"\/pt-br\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agonista dual GLP-1\/GIP \u2014 efeitos metab\u00f3licos mais amplos<\/li>\n<li><a href=\"\/pt-br\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived metabolic peptide \u2014 alternative-mechanism fat-loss studies<\/li>\n<li><a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, preservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Pept\u00eddeo quim\u00e9rico de 25 aa \u2014 sequ\u00eancia de homing CKGGRAKDC + ligador GG + pr\u00f3-apopt\u00f3tico D(KLAKLAK)\u2082<br \/>\n\u2705 Alvo: prohibitin-1 + anexina A2 no endot\u00e9lio capilar do tecido adiposo branco<br \/>\n\u2705 Induz apoptose do endot\u00e9lio vascular \u2192 priva\u00e7\u00e3o de suprimento sangu\u00edneo aos adip\u00f3citos<br \/>\n\u2705 ~11% de perda de peso em macacos rhesus em 4 semanas (Barnhart 2011, Sci Trans Med)<br \/>\n\u2705 Pept\u00eddeo quim\u00e9rico MD Anderson\/Kolonin-Arap-Pasqualini; PM ~2.611 Da<\/p>\n<p><strong>Adipotide\/FTPP<\/strong> contains CKGGRAKDC-GG-D(KLAKLAK)\u2082 chimeric peptide. <em>Documented nephrotoxicity in primate studies \u2014 context only.<\/em><\/p>","protected":false},"featured_media":71465,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6509,6504,6506,6502,6505,6507,6508,6494],"class_list":["post-71456","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-adipose-vasculature","product_tag-adipotide","product_tag-chimeric-peptide","product_tag-fat-loss-research","product_tag-ftpp","product_tag-pro-apoptotic-peptide","product_tag-prohibitin-targeting","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71456"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71465"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71456"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71456"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71456"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}